Which is better, RPRX or SUPN?

On the Buffett-Fit framework, Royalty Pharma plc (RPRX) currently grades higher than SUPN — 66/100 (C grade) vs 20/100 (F). That said, "better" depends on which framework you trust — RPRX wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; SUPN wins on none. The full pillar breakdown is on this page.

Should I buy RPRX or SUPN?

This page is an educational comparison, not investment advice. Both RPRX and SUPN are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is RPRX better than SUPN for value investing?

On the Buffett-style value-investing framework, RPRX currently grades higher — 66/100 vs 20/100, a 46-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between RPRX and SUPN on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). RPRX currently scores 66/100 (C grade); SUPN scores 20/100 (F grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, RPRX or SUPN?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. RPRX and SUPN are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, RPRX or SUPN?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are RPRX and SUPN both Healthcare stocks?

Yes — both Royalty Pharma plc (RPRX) and Supernus Pharmaceuticals, Inc. (SUPN) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this RPRX vs SUPN comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Royalty Pharma

Supernus Pharmaceuticals

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

RPRX

Royalty Pharma

Market cap

$23.44B

Sector

Healthcare

SUPN

Supernus Pharmaceuticals

Market cap

$2.8B

Sector

Healthcare

Overall winner

Royalty Pharma RPRX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	RPRX	SUPN	Winner
Warren Buffett	66C	20F	RPRX
Benjamin Graham	84A	43D	RPRX
Philip Fisher	65C	31F	RPRX
Peter Lynch	60C	13F	RPRX
Joel Greenblatt	40D	2F	RPRX
Charlie Munger	68D	26F	RPRX
Terry Smith	58D	24F	RPRX

Side-by-side metrics

Metric	RPRX	SUPN
Market cap	$23.44B	$2.8B
P/E (TTM)	27.6x	-
EV/EBIT	19.9x	-
ROIC (TTM)	8.43%	-2.16%
Gross margin	99.95%	89.42%
Net margin	33.91%	-3.74%
Revenue CAGR 5y	0.96%	5.53%
EPS CAGR 5y	11.83%	-
Debt / Equity	1.3x	0.0x
Dividend yield	1.72%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

RPRX leads on

ROIC (TTM)8.43%vs -2.16%+126%
Net margin33.91%vs -3.74%+111%
Dividend yield1.72%vs 0.0%+100%
Market cap$23.44Bvs $2.8B+88%

SUPN leads on

P/E (TTM)-vs 27.6x+127%
EV/EBIT-vs 19.9x+126%
Debt / Equity0.0xvs 1.3x+97%
Revenue CAGR 5y5.53%vs 0.96%+83%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Royalty Pharma

Supernus Pharmaceuticals

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like RPRX

More like SUPN

Related on invest-like

Key terms in this analysis